Ação de um novo protótipo anti-hipertensivo (LASSBio-897) sobre o sistema cardiovascular de gatos

Abstract

Systemic hypertension (SH) is one of the main cardiovascular risk factors. It is a disease of often late detection due to its slow evolution and silence. Both, cats and man, SH is characterized by high and sustained levels of blood pressure (BP). The main consequences of SH are injuries in major organs, such as eyes, brain, kidneys, and heart. In order to avoid major problems generated by SH, researches have been conducted to identify new molecules capable to control SH. Recently a new prototype (LASSBio-897), was developed by the laboratory of Bioactive Substances (LASSBio) at the Federal University of Rio de Janeiro (UFRJ), which demonstrated significant vasodilation activity in rats. For a better understanding of these prototype, pre-clinical studies are needed in another specie, witch will serve to determine the pharmacokinetics and safety of the molecule. Therefore it is necessary, obeying the toxicological profile of the prototype, to pre-establish and administrate doses to another specie, in these case cats. In order to identify possible cardiovascular effects some complementary exams are needed, such as electrocardiogram, echodopplercardiogram and blood pressure measurement, besides it`s necessary to identify possible toxicity effects, so hematological exams are also needed, such as hemogram and serum biochemical. The aim of the study was to prove vasodilator effect induce by LASSBio-897 in cats. This effect was seen specially for the smallest dose of LASSBio-897 proposed.